When Bryce Klontz started his role as CEO and President of New View Surgical six years ago, he already had two decades of medtech experience under his belt. Experience he’s since leveraged to close out a successful Series B round of financing and secure 510(k) FDA clearance.

Before joining New View, Bryce was the Vice President of Commercial Strategy and Emerging Markets for Covidien. There, he expanded the medical devices conglomerate across Asia, Africa, Latin America, and the Middle East.

Under Bryce’s leadership, New View is pioneering laparoscopic technology. Their VisionPort combines the laparoscope, camera, light, and access port into a single instrument that promises to slash the cost and preoperative time of a laparoscopy.

The device also shows the potential to reduce the number of incisions needed for some surgeries and widen access to the surgery by making laparoscopic technology easier to transport to the patient’s location.

These innovations garnered New View Surgical widespread recognition. At the Keiretsu Forum Investor Capital Expo in 2020, angel investors selected New View as the “Most Valued Company.” Funding and regulatory successes followed, with the business attracting over $14 million in total capital and securing 510(k) clearance.

In this interview, Bryce Klontz shares insights from his decades of experience in the surgical devices space, from building relationships of trust with regulators and investors to working closely with practitioners to perfect product-market fit.